The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells
Open accessAbstract
// Marie-Magdelaine Coudé 1,2,* , Thorsten Braun 1,3,* , Jeannig Berrou 1 , Mélanie Dupont 1 , Sibyl Bertrand 1 , Aline Masse 1 , Emmanuel Raffoux 1,4 , Raphaël Itzykson 1,4 , Marc Delord 5 , Maria E. Riveiro 6 , Patrice Herait 7 , André Baruchel 1,8 , Hervé Dombret 1,4 and Claude Gardin 1,3 1 Laboratoire de Transfert des Leucémies, Institut Universitaire d’Hématologie, University Paris VII, Paris, France 2 Laboratory of Hematology, Hôpital Saint-Louis (Assistance Publique - Hôpitaux de Paris and University Paris VII), Paris, France 3 Hematology Department, Hôpital Avicenne (Assistance Publique - Hôpitaux de Paris and University Paris XIII), Bobigny, France 4 Leukemia Unit, Hematology Department, Hôpital Saint-Louis (Assistance Publique - Hôpitaux de Paris and University Paris VII), Paris, France 5 Bioinformatics, Institut Universitaire d’Hématologie, University Paris VII, Paris, France 6 Oncology Therapeutic Development, Clichy, France 7 Oncoethix, Lausanne, Switzerland 8 Department of Pediatric Hemato-Immunology, Hôpital Robert Debré (Assistance Publique - Hôpitaux de Paris and University Paris VII), Paris, France * These authors have contributed equally to this work Correspondence to: Claude Gardin, email: // Keywords : OTX015, BET inhibitors, c-MYC, HEXIM1, acute leukemias Received : November 26, 2014 Accepted : April 08, 2015 Published : May 14, 2015 Abstract The bromodomain (BRD) and extraterminal (BET) proteins including BRD2, BRD3 and BRD4 have been identified as key targets for leukemia maintenance. A novel oral inhibitor of BRD2/3/4, the thienotriazolodiazepine compound OTX015, suitable for human use, is available. Here we report its biological effects in AML and ALL cell lines and leukemic samples. Exposure to OTX015 lead to cell growth inhibition, cell cycle arrest and apoptosis at submicromolar concentrations in acute leukemia cell lines and patient-derived leukemic cells, as described with the canonical JQ1 BET inhibitor. Treatment with JQ1 and OTX15 induces similar gene expression profiles in sensitive cell lines, including a c-MYC decrease and an HEXIM1 increase. OTX015 exposure also induced a strong decrease of BRD2, BRD4 and c-MYC and increase of HEXIM1 proteins, while BRD3 expression was unchanged. c-MYC , BRD2, BRD3, BRD4 and HEXIM1 mRNA levels did not correlate however with viability following exposure to OTX015. Sequential combinations of OTX015 with other epigenetic modifying drugs, panobinostat and azacitidine have a synergic effect on growth of the KASUMI cell line. Our results indicate that OTX015 and JQ1 have similar biological effects in leukemic cells, supporting OTX015 evaluation in a Phase Ib trial in relapsed/refractory leukemia patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene Ontology: tool for the unification of biology
Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, A. P., Dolinski, K., Dwight, S. S., Eppig, J. T., et al. (2000) · Nature Genetics · doi:10.1038/75556 · Cited by 43,206
Controlling the false discovery rate in behavior genetics research
Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N., & Golani, I. (2001) · Behavioural Brain Research · doi:10.1016/s0166-4328(01)00297-2 · Cited by 4,146
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S. C., Chung, C.-W., Hopf, C., Savitski, M. M., et al. (2011) · Nature · doi:10.1038/nature10509 · Cited by 1,503
Estey, E., & Döhner, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69780-8 · Cited by 1,296
c-Myc Regulates Transcriptional Pause Release
Rahl, P. B., Lin, C. Y., Seila, A. C., Flynn, R. A., McCuine, S., Burge, C. B., Sharp, P. A., & Young, R. A. (2010) · Cell · doi:10.1016/j.cell.2010.03.030 · Cited by 1,279
A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia
Gröschel, S., Sanders, M. A., Hoogenboezem, R., de Wit, E., Bouwman, B. A. M., Erpelinck, C., van der Velden, V. H. J., Havermans, M., Avellino, R., van Lom, K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.02.019 · Cited by 687
Brd4 Coactivates Transcriptional Activation of NF-κB via Specific Binding to Acetylated RelA
Huang, B., Yang, X.-D., Zhou, M.-M., Ozato, K., & Chen, L.-F. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01365-08 · Cited by 579
BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma.
French, C. A., Miyoshi, I., Kubonishi, I., Grier, H. E., Pérez‐Atayde, A. R., & Fletcher, J. A. (2003) · PubMed · Cited by 501
Yik, J. H. N., Chen, R., Nishimura, R., Jennings, J. L., Link, A. J., & Zhou, Q. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00388-5 · Cited by 466
Mrózek, K., Marcucci, G., Nicolet, D., Maharry, K. S., Becker, H., Whitman, S. P., Metzeler, K. H., Schwind, S., Wu, Y.-Z., Kohlschmidt, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.4738 · Cited by 406
Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription
Bisgrove, D. A., Mahmoudi, T., Henklein, P., & Verdin, E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705053104 · Cited by 387
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
Ott, C. J., Kopp, N., Bird, L., Paranal, R. M., Qi, J., Bowman, T., Rodig, S. J., Kung, A. L., Bradner, J. E., & Weinstock, D. M. (2012) · Blood · doi:10.1182/blood-2012-02-413021 · Cited by 374
The Double Bromodomain Proteins Brd2 and Brd3 Couple Histone Acetylation to Transcription
LeRoy, G., Rickards, B., & Flint, S. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.01.018 · Cited by 372
An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia
Knoechel, B., Roderick, J. E., Williamson, K. E., Zhu, J., Lohr, J. G., Cotton, M. J., Gillespie, S. M., Fernandez, D., Ku, M., Wang, H., et al. (2014) · Nature Genetics · doi:10.1038/ng.2913 · Cited by 367
MLL3 Is a Haploinsufficient 7q Tumor Suppressor in Acute Myeloid Leukemia
Chen, C., Liu, Y., Rappaport, A. R., Kitzing, T., Schultz, N., Zhao, Z., Shroff, A. S., Dickins, R. A., Vakoc, C. R., Bradner, J. E., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.016 · Cited by 311
The transcriptional program of a human B cell line in response to Myc
Schuhmacher, M. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.2.397 · Cited by 310
Nechaev, S., & Adelman, K. (2011) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.11.001 · Cited by 265
Zhou, Q., & Yik, J. H. N. (2006) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00011-06 · Cited by 261
Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
Chaidos, A., Caputo, V., Gouvedenou, K., Liu, B., Marigo, I., Chaudhry, M. S., Rotolo, A., Tough, D. F., Smithers, N. N., Bassil, A. K., et al. (2014) · Blood · doi:10.1182/blood-2013-01-478420 · Cited by 203
Grayson, A. R., Walsh, E. M., Cameron, M. J., Godec, J., Ashworth, T., Ambrose, J. M., Aserlind, A. B., Wang, H., Evan, G. I., Kluk, M. J., et al. (2014) · Oncogene · doi:10.1038/onc.2013.126 · Cited by 184
Chen, C., Liu, Y., Lu, C., Cross, J. R., Morris, J. P., Shroff, A. S., Ward, P. S., Bradner, J. E., Thompson, C., & Lowe, S. W. (2013) · Genes & Development · doi:10.1101/gad.226613.113 · Cited by 182
Dawson, M. A., Gudgin, E. J., Horton, S. J., Giotopoulos, G., Meduri, E., Robson, S., Cannizzaro, E., Osaki, H., Wiese, M., Putwain, S., et al. (2014) · Leukemia · doi:10.1038/leu.2013.338 · Cited by 175
Herrmann, H., Blatt, K., Shi, J., Gleixner, K. V., Cerny‐Reiterer, S., Müllauer, L., Vakoc, C. R., Sperr, W. R., Horny, H., Bradner, J. E., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.733 · Cited by 160
Bots, M. L., Verbrugge, I., Martin, B. P., Salmon, J. M., Ghisi, M., Baker, A., Stanley, K. L., Shortt, J., Ossenkoppele, G. J., Zuber, J. A., et al. (2014) · Blood · doi:10.1182/blood-2013-03-488114 · Cited by 131
7SK RNA, a non-coding RNA regulating P-TEFb, a general transcription factor
Diribarne, G., & Bensaude, O. (2009) · RNA Biology · doi:10.4161/rna.6.2.8115 · Cited by 130
Evaluating Response to Antineoplastic Drug Combinations in Tissue Culture Models
Reynolds, C. P., & Maurer, B. J. (2005) · Humana Press eBooks · doi:10.1385/1-59259-869-2:173 · Cited by 126
BET bromodomain inhibitors: a patent review
Garnier, J., Sharp, P. P., & Burns, C. J. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.859244 · Cited by 122
Emadali, A., Rousseaux, S., Costa, J. B., Rome, C., Duley, S., Hamaidia, S., Betton-Fraisse, P., Debernardi, A., Leroux, D., Bernay, B., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202034 · Cited by 89
Novel drugs for older patients with acute myeloid leukemia
Bravo, G. M., & Garcia‐Manero, G. (2014) · Leukemia · doi:10.1038/leu.2014.244 · Cited by 85
Liu, S., Walker, S. R., Nelson, E. A., Cerulli, R. A., Xiang, M. H., Toniolo, P. A., Qi, J., Stone, R. M., Wadleigh, M., Bradner, J. E., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0341 · Cited by 67
Nucleophosmin Interacts with HEXIM1 and Regulates RNA Polymerase II Transcription
Gurumurthy, M., Tan, C. H., Ng, R., Zeiger, L., Lau, M. J., Lee, J., Dey, A., Philp, R. J., Li, Q., Lim, T. M., et al. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.02.055 · Cited by 58
Diagnostic Testing for IDH1 and IDH2 Variants in Acute Myeloid Leukemia
Patel, K. P., Barkoh, B. A., Chen, Z., Ma, D., Reddy, N., Medeiros, L. J., & Luthra, R. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2011.06.004 · Cited by 55
Dey, A., Chao, S., & Lane, D. P. (2007) · Cell Cycle · doi:10.4161/cc.6.15.4556 · Cited by 53
BRD4: A BET(ter) target for the treatment of AML?
Valent, P., & Zuber, J. A. (2014) · Cell Cycle · doi:10.4161/cc.27859 · Cited by 28
Short Hairpin RNA Screen Reveals Bromodomain Proteins as Novel Targets in Acute Myeloid Leukemia
Blobel, G. A., Kalota, A., Sanchez, P. V., & Carroll, M. P. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.019 · Cited by 26
Development of a Malignancy-Associated Proteomic Signature for Diffuse Large B-Cell Lymphoma
Romesser, P. B., Perlman, D. H., Faller, D. V., Costello, C. E., McComb, M. E., & Denis, G. V. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080707 · Cited by 16
Cited by
Differentiation therapy revisited
de Thé, H. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.103 · Cited by 462
BET Proteins as Targets for Anticancer Treatment
Stathis, A., & Bertoni, F. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0605 · Cited by 463
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
Berthon, C., Raffoux, E., Thomas, X., Vey, N., Gomez-Roca, C., Yee, K., Taussig, D. C., Rezai, K., Roumier, C., Herait, P., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00247-1 · Cited by 420
Self-citationAmorim, S., Stathis, A., Gleeson, M., Iyengar, S., Magarotto, V., Leleu, X., Morschhauser, F., Karlin, L., Broussais, F., Rezai, K., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)00021-1 · Cited by 417
Self-citationTranscriptional Dependencies in Diffuse Intrinsic Pontine Glioma
Nagaraja, S., Vitanza, N. A., Woo, P. J., Taylor, K. R., Liu, F., Zhang, L., Li, M., Meng, W., Ponnuswami, A., Sun, W., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.011 · Cited by 396
Metadata
- Authors
- Coudé, M.-M., Braun, T., Berrou, J., Dupont, M., Bertrand, S., Masse, A., Raffoux, E., Itzykson, R., Delord, M., Riveiro, M. E., Herait, P., Baruchel, A., Dombret, H., & Gardin, C.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-05-14
- Volume
- 6
- Issue
- 19
- Pages
- 17698-17712
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1945032888
- Cited by
- 274
- References
- 39
- FWCI
- 11.84
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
